A detailed history of Rafferty Asset Management, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 90,348 shares of FDMT stock, worth $531,246. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,348
Previous 95,565 5.46%
Holding current value
$531,246
Previous $2.01 Million 51.32%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.81 - $27.22 $56,395 - $142,006
-5,217 Reduced 5.46%
90,348 $976,000
Q2 2024

Aug 13, 2024

SELL
$20.93 - $30.01 $2.03 Million - $2.91 Million
-96,816 Reduced 50.33%
95,565 $2.01 Million
Q1 2024

May 13, 2024

BUY
$17.03 - $35.87 $1.12 Million - $2.36 Million
65,792 Added 51.97%
192,381 $6.13 Million
Q4 2023

Feb 13, 2024

SELL
$9.76 - $21.25 $338,642 - $737,311
-34,697 Reduced 21.51%
126,589 $2.56 Million
Q3 2023

Nov 13, 2023

SELL
$12.64 - $19.76 $453,384 - $708,771
-35,869 Reduced 18.19%
161,286 $2.05 Million
Q2 2023

Aug 11, 2023

BUY
$15.16 - $23.26 $945,483 - $1.45 Million
62,367 Added 46.27%
197,155 $3.56 Million
Q1 2023

May 11, 2023

BUY
$15.45 - $23.19 $1.34 Million - $2.01 Million
86,855 Added 181.2%
134,788 $2.32 Million
Q4 2022

Feb 13, 2023

BUY
$6.85 - $25.46 $328,341 - $1.22 Million
47,933 New
47,933 $1.06 Million
Q2 2022

Aug 12, 2022

SELL
$5.68 - $15.99 $407,676 - $1.15 Million
-71,774 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$13.16 - $22.64 $51,837 - $89,178
-3,939 Reduced 5.2%
71,774 $1.09 Million
Q4 2021

Feb 10, 2022

BUY
$19.56 - $32.94 $1.48 Million - $2.49 Million
75,713 New
75,713 $1.66 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $190M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.